- Home
- OGN
OGN
Organon & Co.
as 07-26-2024 4:00pm EST
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 5.4B | IPO Year: | N/A |
| Target Price: | $23.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.09 | EPS Growth: | 40.07 |
| 52 Week Low/High: | $10.84 - $24.08 | Next Earning Date: | 08-06-2024 |
| Revenue: | $6,347,000,000 | Revenue Growth: | 3.29% |
| Revenue Growth (this year): | 3.78% | Revenue Growth (next year): | 2.28% |
Stock Insider Trading Activity of Organon & Co. (OGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weaver Kirke | OGN | Gen. Counsel & Corp. Secy. | Feb 22 '24 | Buy | $18.36 | 2,720 | $49,938.93 | 15,181 | SEC Form 4 |
Latest Organon & Co. News
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company
Zacks
2 days ago
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Argus Research
3 days ago
OGN: Rating increased to a HOLD
Argus Research
10 days ago
OGN: What does Argus have to say about OGN?
Argus Research
17 days ago
OGN: What does Argus have to say about OGN?
Business Wire
18 days ago
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
Argus Research
24 days ago
OGN: What does Argus have to say about OGN?
Zacks
a month ago
Do Options Traders Know Something About Organon (OGN) Stock We Don't?
Compare OGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.